Evaluation of molecular monitoring and response milestone of patients with chronic myeloid leukemia to tyrosine kinase inhibitors in Middle Euphrates of Iraq
Background: In the last decade, tremendous changes occurred in the treatment and follow-up of the patients with chronic myeloid leukemia (CML), with continuous update in the close molecular monitoring of treatment for the presence of minimal residual disease.Objectives: The objective of this study was to evaluate the molecular monitoring of patient